Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
158.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 5.50 (3.571%)
Market Cap: £1.36b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Director/PDMR Shareholding

22 May 2007 07:00

Hutchison China Meditech Limited22 May 2007 Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) Director's Shareholding London: Tuesday, 22 May 2007: Chi-Med was informed on 18 May 2007 that Mr.Christian Hogg, Executive Director and Chief Executive Officer of Chi-Med,purchased 70,000 ordinary shares of US$1 each in Chi-Med (the "Shares") at aprice of 153p each on 18 May 2007. Following this purchase, Mr. Hogg is beneficially interested in 170,000 Sharesand vested option to subscribe for up to 384,091 Shares, representingapproximately 1.1% of the current issued share capital of Chi-Med. Ends Enquiries Chi-Med Telephone: +852 2121 8200 Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571 Anthony Carlisle Mobile: +44 (0) 7973 611 888 Yvonne Alexander Mobile: +44 (0) 7866 610 682 About Chi-Med Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and was admitted to trading on the Alternative InvestmentMarket of the London Stock Exchange in May 2006. Chi-Med is focused onresearching, developing, manufacturing, and selling pharmaceuticals, healthsupplements and other consumer health and personal care products derived fromTraditional Chinese Medicine and botanical ingredients. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of The Stock Exchange of Hong Kong Limited. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jun 20197:00 amRNSSecondary Offering of American Depositary Shares
21st Jun 20194:40 pmRNSSecond Price Monitoring Extn
21st Jun 20194:35 pmRNSPrice Monitoring Extension
19th Jun 20194:35 pmRNSPrice Monitoring Extension
14th Jun 20199:00 amRNSSurufatinib Phase III Study Meets Primary Endpoint
12th Jun 20199:18 amRNSBlock Admission Applications & Total Voting Rights
10th Jun 201912:07 pmRNSSecond Price Monitoring Extn
10th Jun 201912:02 pmRNSPrice Monitoring Extension
6th Jun 20197:00 amRNSDisclosure Update
31st May 20194:40 pmRNSSecond Price Monitoring Extn
31st May 20194:35 pmRNSPrice Monitoring Extension
29th May 201912:06 pmRNSResults of Extraordinary General Meeting
22nd May 201911:03 amRNSGrant of Share Options under Share Option Scheme
3rd May 20197:00 amRNSNotice of EGM & Shareholder Circular
24th Apr 20191:54 pmRNSResults of AGM
15th Apr 20197:30 amRNSDisclosure Update
15th Apr 20197:00 amRNSHK Listing Application - Proposed Global Offering
29th Mar 20197:00 amRNSStart of Phase IIb/III Surufatinib Trial in China
28th Mar 20197:30 amRNSSavolitinib Lung Cancer Presentations at AACR
25th Mar 20197:00 amRNSVesting of awards under Long Term Incentive Plan
21st Mar 20197:00 amRNSChi-Med 2018 Annual Report and Notice of AGM
11th Mar 201912:54 pmRNSPublication of Form 20-F
11th Mar 20197:00 amRNS2018 FY Results and Key Clinical Programs Update
12th Feb 20197:00 amRNSSavolitinib PRCC Data to be presented at ASCO GU
8th Feb 20197:00 amRNSChi-Med to Announce 2018 Final Results
7th Jan 20197:00 amRNSChi-Med Presents at JPM Healthcare Conference
31st Dec 20187:00 amRNSBlocklisting Six Monthly Return
31st Dec 20187:00 amRNSTotal Voting Rights
24th Dec 201812:41 pmRNSSecond Price Monitoring Extn
24th Dec 201812:36 pmRNSPrice Monitoring Extension
20th Dec 20187:13 amRNSChi-Med announce Savolitinib program update
20th Dec 20187:00 amRNSAmendment to Lilly Agreement on Fruquintinib
14th Dec 20187:21 amRNSTR-1: Form for notification of major holdings
30th Nov 20187:00 amRNSTotal Voting Rights
29th Nov 20188:00 amRNSChi-Med Enters into Multiple Collaborations
26th Nov 20187:00 amRNSFirst Commercial Launch of Fruquintinib Capsules
16th Nov 20187:00 amRNSPhase III FALUCA Trial Results for Fruquintinib
31st Oct 20187:00 amRNSTotal Voting Rights
22nd Oct 201810:05 amRNSGrant of Share Options under Share Option Scheme
18th Oct 20187:00 amRNSChi-Med Initiates a Ph I Trial of HMPL-523 for AML
5th Oct 20187:00 amRNSAppointment of HSBC Bank plc as Broker in London
5th Sep 20187:00 amRNSFruquintinib Approved for CRC in China
31st Aug 20187:00 amRNSTotal Voting Rights
7th Aug 201810:00 amRNSGrant of Share Options under Share Option Scheme
27th Jul 20187:00 amRNS2018 Interim Results and Clinical Programs Update
23rd Jul 20187:00 amRNSStart of Sulfatinib US Phase Ib/II PoC trial
29th Jun 20187:02 amRNSTotal Voting Rights
29th Jun 20187:01 amRNSBlocklisting Six Monthly Return
29th Jun 20187:00 amRNSChi-Med to Announce Half-Year Financial Results
7th Jun 201810:00 amRNSGrant of Share Options under Share Option Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.